GSK Reports the US FDA’s Approval of Nucala (Mepolizumab) for Chronic Obstructive Pulmonary Disease (COPD)

Shots: The US FDA has approved Nucala as an add-on treatment for inadequately controlled COPD & eosinophilic phenotype based on the P-III (MATINEE & METREX) trial; EMA & NMPA’s submissions are under review MATINEE assessed Nucala (n=403; 100mg, SC, Q4W) vs PBO (n=401) in COPD pts (n=804) with type 2 inflammation while METREX evaluated it…

ByRidhi RastogiMay 23, 2025

AstraZeneca at ACR 2023: Andrew Menzies-Gow Highlights Data from the MANDARA Study

Shots: Andrew Menzies-Gow, in a stimulating conversation with PharmaShots, shares the insights from the Phase III MANDARA study that evaluates Fasenra (benralizumab) vs. mepolizumab for patients with relapsing or refractory EGPA Five out of the 18 abstracts presented by AstraZeneca at ACR were from the MANDARA study. Apart from the positive endpoints of the MANDARA…

BySaurabh ChaubeyFebruary 6, 2024

Andrew Menzies-Gow Shares Insights from Phase III MANDARA Trial of Fasenra for EGPA Patients

Shots While sharing the details on Fasenra, Andrew highlights the unmet medical need in the healthcare sector as there’s only one approved treatment for EGPA With mepolizumab as the comparator drug for the trial, Andrew shares the positive results in achieving remission rates. Andrew sheds light on the unique mechanism of benralizumab that directly targets…

BySaurabh ChaubeyDecember 4, 2023

GSK Reports the US FDA’s Approval of Nucala (Mepolizumab) for Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca at ACR 2023: Andrew Menzies-Gow Highlights Data from the MANDARA Study

Andrew Menzies-Gow Shares Insights from Phase III MANDARA Trial of Fasenra for EGPA Patients

Contact US

OUR INFORMATION

FOLLOW US